Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04171219 · ClinicalTrials.gov registry record · Phase 2
Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT04171219: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT04171219 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04171219, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects of talabostat and pembrolizumab and to see how well they work for the treatment of solid cancers that have spread to other places in the body (advanced). Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talabostat and pembrolizumab may help control the disease.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Talabostat Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-03-19 |
| Est. Completion | 2025-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04171219
The ClinicalTrials.gov registry entry for NCT04171219 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04171219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04171219 about?
NCT04171219 is a clinical study titled "Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers". This phase II trial studies the side effects of talabostat and pembrolizumab and to see how well they work for the treatment of solid cancers that have spread to other places in the body (advanced). Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth....
What is the current status of trial NCT04171219?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2020-03-19. Estimated completion is 2025-03-11.
What interventions are being tested in trial NCT04171219?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Talabostat Mesylate (DRUG).
Who is sponsoring clinical trial NCT04171219?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.